Analysis of the IGF-II receptor gene copy number in breast carcinoma.

Por Hébert, E., Herbelin, C., Bougnoux, P.
Publicado em 1994

Interferon-induced differentiation of U937 cells. Comparison with other agents that promote differentiation of human myeloid or monocytelike cell lines.

Por Hattori, T, Pack, M, Bougnoux, P, Chang, Z L, Hoffman, T
Publicado em 1983

Activation of the oxidative burst in human monocytes is associated with inhibition of methionine-dependent methylation of neutral lipids and phospholipids.

Por Bonvini, E, Bougnoux, P, Stevenson, H C, Miller, P, Hoffman, T
Publicado em 1984

alpha-Linolenic acid content of adipose breast tissue: a host determinant of the risk of early metastasis in breast cancer.

Por Bougnoux, P., Koscielny, S., Chajès, V., Descamps, P., Couet, C., Calais, G.
Publicado em 1994

Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial

Por Bougnoux, P, Hajjaji, N, Ferrasson, M N, Giraudeau, B, Couet, C, Le Floch, O
Publicado em 2009

N-6 polyunsaturated fatty acids in human breast carcinoma phosphatidylethanolamine and early relapse.

Por Lanson, M., Bougnoux, P., Besson, P., Lansac, J., Hubert, B., Couet, C., Le Floch, O.
Publicado em 1990

Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells.

Por Hoffman, T, Hirata, F, Bougnoux, P, Fraser, B A, Goldfarb, R H, Herberman, R B, Axelrod, J
Publicado em 1981

Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma

Por Bougnoux, P, Germain, E, Chajès, V, Hubert, B, Lhuillery, C, Floch, O Le, Body, G, Calais, G
Publicado em 1999

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial

Por Spielmann, M, Tubiana-Hulin, M, Namer, M, Mansouri, H, Bougnoux, P h, Tubiana-Mathieu, N, Lotz, V, Eymard, J C
Publicado em 2002

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

Por Bonneterre, J, Dieras, V, Tubiana-Hulin, M, Bougnoux, P, Bonneterre, M-E, Delozier, T, Mayer, F, Culine, S, Dohoulou, N, Bendahmane, B
Publicado em 2004

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer

Por Lortholary, A, Delozier, T, Monnier, A, Bourgeois, H, Bougnoux, P, Tubiana-Mathieu, N, Riffaud, J Ch, Besson, D, Lotz, V, Gamelin, E
Publicado em 2003

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

Por Amat, S, Bougnoux, P, Penault-Llorca, F, Fétissof, F, Curé, H, Kwiatkowski, F, Achard, J-L, Body, G, Dauplat, J, Chollet, P
Publicado em 2003

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

Por Tubiana-Mathieu, N, Bougnoux, P, Becquart, D, Chan, A, Conte, P-F, Majois, F, Espie, M, Morand, M, Vaissiere, N, Villanova, G
Publicado em 2009

The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine

Por Potier, M, Chantome, A, Joulin, V, Girault, A, Roger, S, Besson, P, Jourdan, M-L, LeGuennec, J-Y, Bougnoux, P, Vandier, C
Publicado em 2011

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

Por Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Publicado em 2013